These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 31871094)

  • 1. VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in
    Hamrick JC; Docquier JD; Uehara T; Myers CL; Six DA; Chatwin CL; John KJ; Vernacchio SF; Cusick SM; Trout REL; Pozzi C; De Luca F; Benvenuti M; Mangani S; Liu B; Jackson RW; Moeck G; Xerri L; Burns CJ; Pevear DC; Daigle DM
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1
    Piccirilli A; Segatore B; Brisdelli F; Amicosante G; Perilli M
    Int J Antimicrob Agents; 2021 Jan; 57(1):106228. PubMed ID: 33246038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Next-Generation β-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli.
    Roach EJ; Uehara T; Daigle DM; Six DA; Khursigara CM
    Microbiol Spectr; 2021 Oct; 9(2):e0091821. PubMed ID: 34494877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
    Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
    Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Lomovskaya O; Castanheira M; Lindley J; Rubio-Aparicio D; Nelson K; Tsivkovski R; Sun D; Totrov M; Loutit J; Dudley M
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0044023. PubMed ID: 37800963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria.
    Abdelraouf K; Almarzoky Abuhussain S; Nicolau DP
    J Antimicrob Chemother; 2020 Dec; 75(12):3601-3610. PubMed ID: 32862218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Cefepime in Combination with the Novel β-Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum-β-Lactamase-Producing Isolates in
    Kloezen W; Melchers RJ; Georgiou PC; Mouton JW; Meletiadis J
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33431413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.
    Wang X; Zhao C; Wang Q; Wang Z; Liang X; Zhang F; Zhang Y; Meng H; Chen H; Li S; Zhou C; Li H; Wang H
    J Antimicrob Chemother; 2020 Jul; 75(7):1850-1858. PubMed ID: 32154866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria.
    Mushtaq S; Vickers A; Doumith M; Ellington MJ; Woodford N; Livermore DM
    J Antimicrob Chemother; 2021 Jan; 76(1):160-170. PubMed ID: 33305800
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing
    Vázquez-Ucha JC; Lasarte-Monterrubio C; Guijarro-Sánchez P; Oviaño M; Álvarez-Fraga L; Alonso-García I; Arca-Suárez J; Bou G; Beceiro A;
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0167621. PubMed ID: 34807754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain.
    Hernández-García M; García-Castillo M; Nieto-Torres M; Bou G; Ocampo-Sosa A; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Oliver A; Ruiz-Garbajosa P; Cantón R
    Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):279-296. PubMed ID: 38041722
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Karlowsky JA; Hackel MA; Wise MG; Six DA; Uehara T; Daigle DM; Cusick SM; Pevear DC; Moeck G; Sahm DF
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0128122. PubMed ID: 36541767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-β-Lactamases.
    Krajnc A; Brem J; Hinchliffe P; Calvopiña K; Panduwawala TD; Lang PA; Kamps JJAG; Tyrrell JM; Widlake E; Saward BG; Walsh TR; Spencer J; Schofield CJ
    J Med Chem; 2019 Sep; 62(18):8544-8556. PubMed ID: 31454231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
    Liu B; Trout REL; Chu GH; McGarry D; Jackson RW; Hamrick JC; Daigle DM; Cusick SM; Pozzi C; De Luca F; Benvenuti M; Mangani S; Docquier JD; Weiss WJ; Pevear DC; Xerri L; Burns CJ
    J Med Chem; 2020 Mar; 63(6):2789-2801. PubMed ID: 31765155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
    Blanco-Martín T; Alonso-García I; González-Pinto L; Outeda-García M; Guijarro-Sánchez P; López-Hernández I; Pérez-Vázquez M; Aracil B; López-Cerero L; Fraile-Ribot P; Oliver A; Vázquez-Ucha JC; Beceiro A; Bou G; Arca-Suárez J;
    Int J Antimicrob Agents; 2024 May; 63(5):107150. PubMed ID: 38513748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
    Le Terrier C; Freire S; Nordmann P; Poirel L
    Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of
    Chatwin CL; Hamrick JC; Trout REL; Myers CL; Cusick SM; Weiss WJ; Pulse ME; Xerri L; Burns CJ; Moeck G; Daigle DM; John K; Uehara T; Pevear DC
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0055221. PubMed ID: 34001510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Specific Metallo-β-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-Positive
    Zalacain M; Lozano C; Llanos A; Sprynski N; Valmont T; De Piano C; Davies D; Leiris S; Sable C; Ledoux A; Morrissey I; Lemonnier M; Everett M
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33820763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection.
    Moeck G; Gasink LB; Mendes RE; Woosley LN; Dorr M; Chen H; Wagenlehner FM; Henkel T; McGovern PC
    Antimicrob Agents Chemother; 2024 Jul; 68(7):e0023624. PubMed ID: 38780262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.